ReviewPsychopharmacology2026
The process of angiogenesis in neurodegeneration-pathomechanisms and new therapeutic interventions.
Review in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- tRNA-derived small RNAs in ocular neovascular diseases: A systematic review.Non-coding RNA research · 2026Review
- An Activity-Dependent NEPAS-PTX3 Axis Links Neurovascular and Myelin Deficits to Cognitive Impairment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Comparison of automated white matter lesion segmentation approaches for use in large, multi-site data analyses in Parkinson's disease.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNeurodegenerative diseases are a leading cause of disability worldwide, and recent evidence highlights the role of angiogenesis in their pathophysiology. This review aimed to explore molecular and metabolic links between neurodegeneration and angiogenesis, and to assess the potential of antiangiogenic drugs as therapeutic agents.
methodsA targeted literature search of experimental and clinical studies was performed, focusing on angiogenesis-related mechanisms in neurodegeneration and the effects of antiangiogenic compounds on neuronal and vascular function.
resultsAntiangiogenic agents have been shown to promote synaptic plasticity, enhance neurotransmission, and exert anti-inflammatory effects. They also modulate vascular remodeling, which supports optimal cerebral blood flow and nutrient delivery to neurons. These actions may counteract key pathological processes in neurodegenerative diseases and help preserve cognitive and motor function.
conclusionsModulation of angiogenesis represents a promising therapeutic approach in neurodegenerative disorders. Antiangiogenic drugs may address both vascular and neuronal dysfunction, offering a potential avenue for disease-modifying treatments. Further preclinical and clinical research is needed to validate their safety, efficacy, and long-term benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.